These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 17610348)

  • 1. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome.
    Bulcão C; Ribeiro-Filho FF; Sañudo A; Roberta Ferreira SG
    Am J Cardiovasc Drugs; 2007; 7(3):219-24. PubMed ID: 17610348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
    Bulcão C; Giuffrida FM; Ribeiro-Filho FF; Ferreira SR
    Braz J Med Biol Res; 2007 Feb; 40(2):229-35. PubMed ID: 17273659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
    Bays HE; Stein EA; Shah AK; Maccubbin DL; Mitchel YB; Mercuri M
    Am J Cardiol; 2002 Nov; 90(9):942-6. PubMed ID: 12398959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe.
    Kater AL; Batista MC; Ferreira SR
    Metabolism; 2010 Jun; 59(6):921-6. PubMed ID: 20199786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance.
    Moutzouri E; Liberopoulos E; Mikhailidis DP; Kostapanos MS; Kei AA; Milionis H; Elisaf M
    Int J Clin Pract; 2011 Nov; 65(11):1141-8. PubMed ID: 21995692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose.
    Krysiak R; Okopien B
    Atherosclerosis; 2012 Dec; 225(2):403-7. PubMed ID: 23107042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
    Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
    J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies.
    Karakas SE; Banaszewska B; Spaczynski RZ; Pawelczyk L; Duleba A
    Gynecol Endocrinol; 2013 May; 29(5):483-7. PubMed ID: 23480783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes.
    Bellia A; Rizza S; Galli A; Fabiano R; Donadel G; Lombardo MF; Cardillo C; Sbraccia P; Tesauro M; Lauro D
    Atherosclerosis; 2010 May; 210(1):199-201. PubMed ID: 20018286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
    Panichi V; Paoletti S; Mantuano E; Manca-Rizza G; Filippi C; Santi S; Taccola D; Donadio C; Tramonti G; Innocenti M; Casto G; Consani C; Sbragia G; Franzoni F; Galetta F; Panicucci E; Barsotti G
    Nephrol Dial Transplant; 2006 Feb; 21(2):337-44. PubMed ID: 16249194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
    Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identical LDL-cholesterol lowering but non-identical effects on NF-κB activity: High dose simvastatin vs combination therapy with ezetimibe.
    Rudofsky G; Reismann P; Groener JB; Djuric Z; Fleming T; Metzner C; Grafe IA; Bierhaus A; Nawroth PP
    Atherosclerosis; 2012 Jul; 223(1):190-6. PubMed ID: 22633472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
    Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
    Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients.
    Szendroedi J; Anderwald C; Krssak M; Bayerle-Eder M; Esterbauer H; Pfeiler G; Brehm A; Nowotny P; Hofer A; Waldhäusl W; Roden M
    Diabetes Care; 2009 Feb; 32(2):209-14. PubMed ID: 18957532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials.
    Sun J; Yuan Y; Cai R; Sun H; Zhou Y; Wang P; Huang R; Xia W; Wang S
    BMJ Open; 2015 Mar; 5(3):e007280. PubMed ID: 25818277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of short-term simvastatin treatment on plasma adipokine levels in patients with isolated hypercholesterolemia: A preliminary report.
    Krysiak R; Zmuda W; Okopień B
    Pharmacol Rep; 2014 Oct; 66(5):880-4. PubMed ID: 25149995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.